FinnGen studies published in Nature!

FinnGen brings together the nation-wide network of Finnish biobanks.

Every Finn can be a part of the FinnGen study by giving a biobank consent.
Samples available
546 800
Samples needed by 2023: 520 000
Current data freeze
429 200
combined genotype and health registry data

Samples from biobanks

The FinnGen study will utilise samples collected by a nationwide network of Finnish biobanks. The study is based on combining genome information with digital health care data from national health registries.

Take part

Samples are needed from all over Finland in the thousands, because solutions in the field of personalized healthcare can be found only by looking at large masses. Every Finn can be a part of the FinnGen study by giving a biobank consent.

Everybody benefits

The genome data produced during the project will be owned by the Finnish biobanks, and remain available for researcher purposes. The medical breakthroughs that arise from the project will eventually benefit health care systems and patients globally.

Collaboration is the key

The collaborative nature of the FinnGen research project is exceptional compared to many other studies. The study involves all the same actors as drug development. With this open cooperation, we hope to speed up the emergence of new innovations.

Data freeze 8 results and summary statistics available!

Results can be browsed online using the FinnGen web browser and the summary statistics downloaded
This data freeze consists of >342,000 individuals, almost 20.2 M variants and 2,202 disease endpoints. To get more information about how to access the results and summary statistics, please follow this link:
Birches with the text "New FinnGen GWAS results".


New results from the FinnGen research consortium demonstrate the undeniable benefits of Finnish health research environment for genomic research. Among the wealth of novel genetic discoveries are previously unknown genetic risk factors for many debilitating diseases. These findings have potential to facilitate the development of new therapies.
A large-scale biobank-based study performed in Finland has discovered several new disease genes as well as new insights on how known genetic factors affect disease. The study highlights an underappreciated complexity in the dosage effects of genetic variants.